Integrated Molecular Diagnostics

Based in California, US, and founded in 2016, IMD, Inc. , d. b. a.

Integrated Molecular Diagnostics, is a molecular diagnostics laboratory that focuses on cancer management and diagnostic services. In October 2024, Lab Genomics, a portfolio of Luha Private Equity, acquired Integrated Molecular Diagnostics. Integrated Molecular Diagnostics offers a comprehensive suite of diagnostic services specifically targeting cancer management. The company’s core product offerings include advanced testing methodologies such as histology, immunohistochemistry, flow cytometry, cytogenetics, fluorescence in situ hybridization (FISH), and molecular diagnostics.

These services support community-based pathology groups and oncologists by providing vital insights for managing both first-line and advanced-stage cancer patients. IMD serves a broad client base that includes hospitals and integrated delivery networks (IDNs) mainly across the United States. IMD operates its revenue model through direct transactions with healthcare providers and institutions, primarily relying on B2B partnerships. Clients engage in IMD’s testing services on a per-case basis, which involves submitting samples for analysis and incurring fees for each diagnostic test conducted.